1449432-43-2

Basic information

• Product Name: C₆₄H₁₁₆O₁₆Si₄
• Synonyms: C₆₄H₁₁₆O₁₆Si₄
• CAS NO: 1449432-43-2
• Molecular Weight: 1253.96
• Mol File: 1449432-43-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₆₄H₁₁₆O₁₆Si₄(CAS DataBase Reference)
• NIST Chemistry Reference: C₆₄H₁₁₆O₁₆Si₄(1449432-43-2)
• EPA Substance Registry System: C₆₄H₁₁₆O₁₆Si₄(1449432-43-2)

Safety Data

• Hazardous Substances Data: 1449432-43-2(Hazardous Substances Data)

Upstream product

• 1449432-33-0 (3aS,7aS)-(Z)-1-ethylidene-3a,4,7,7a-tetrahydro-7a-methyl-(6H)-indan-5-one 
• 1449432-40-9 C₂₀H₃₄O₃ 
• 1449432-38-5 C₂₄H₄₆O₂Si 
• 1449432-36-3 C₁₉H₃₆O₂Si 
• 1026056-10-9 C₁₂H₂₀O 
• 1449432-32-9 C₁₄H₂₂O₂ 
• 1044141-08-3 (3a'S,7a'S)-7a'-methyloctahydrospiro([1,3]dioxolane-2,5'-inden)-1'(6'H)-one 
• 118141-48-3 (3aR,7aS)-1,2,3a,4,5,6,7,7a-octahydro-7a-methyl<1H>inden-1,5-dione 
• 17553-86-5 (S)-Halos-Parish ketone 
• 1449432-41-0 (1S,2R,3aS,5S,7aS)-5-[(1,1-dimethylethyl)dimethylsilyl]oxy-1-[(2S)-3,3-ethylenedioxy-6-methylheptan-2-yl]hexahydro-7a-methylindane-1,2-diol 
• 1449432-39-6 (2S)-2-[(3aS,5S,7aS)-5-[(1,1-dimethylethyl)dimethylsilyl]oxyhexahydro-7a-methyl-(3H)-inden-1-yl]-3,3-ethylenedioxy-6-methylheptane 
• 1449432-37-4 (2S)-2-[(3aS,5S,7aS)-5-[(1,1-dimethylethyl)dimethylsilyl]oxyhexahydro-7a-methyl-(3H)-inden-1-yl]-6-methylheptan-3-one 
• 1449432-35-2 (2S)-2-[(3aS,5S,7aS)-5-[(1,1-Dimethylethyl)dimethylsilyl]oxyhexahydro-7a-methyl-(3H)-inden-1-yl]propan-1-al 
• 1449432-34-1 (3aS,5S,7aS)-(Z)-1-ethylidene-5-[(1,1-dimethylethyl)dimethylsilyl]oxyhexahydro-7a-methyl-(1H)-indene 

Downstream Products

• 1449432-44-3 C₃₈H₅₆O₁₅ 

Relevant articles and documents

Synthesis and antitumor activity of des-AB analogue of steroidal saponin OSW-1

Simplified des-AB-type aglycone of antitumor steroidal saponin OSW-1 was concisely prepared starting from readily available Hajos ketone. We further completed the synthesis of des-AB-OSW-1 analogue by the installation of the disaccharide moiety into the des-AB aglycone, and evaluated its antitumor activity. The results indicated that a truncated aglycone drug design strategy based on OSW-1 would be a promising approach for the development of novel antitumor agents.